T-knife is a developer of T cell receptors intended for T cell therapy of cancer. Founded in 2018, T-knife is backed by investors that include RA Capital Management, Boehringer Ingelheim Venture Fund, Andera Partners, and Versant Ventures and is headquartered in Berlin.
FOUNDED:
2018
INDUSTRY:
Biotechnology
You are seconds away from signing up for the hottest list in New York Tech!
Join the millions and keep up with the stories shaping entrepreneurship. Sign up today.
